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A  vaccine  against  malaria  is urgently  needed  for control  and  eventual  eradication.  Different  approaches
are  pursued  to induce  either  sterile  immunity  directed  against  pre-erythrocytic  parasites  or  to mimic
naturally  acquired  immunity  by  controlling  blood-stage  parasite  densities  and  disease  severity.  Pre-
erythrocytic  and  blood-stage  malaria  vaccines  are  often  seen  as  opposing  tactics,  but it is likely that  they
have to be  combined  into  a  multi-stage  malaria  vaccine  to  be optimally  safe  and effective.
Since  many  antigenic  targets  are  shared  between  liver-  and  blood-stage  parasites,  malaria  vaccines
have  the  potential  to elicit  cross-stage  protection  with  immune  mechanisms  against  both  stages  com-
plementing  and  enhancing  each  other.  Here  we  discuss  evidence  from  pre-erythrocytic  and  blood-stage
subunit  and  whole  parasite  vaccination  approaches  that  show  that  protection  against  malaria  is  not  nec-
essarily  stage-speciﬁc.  Parasites  arresting  at late  liver-stages  especially,  can  induce  powerful  blood-stage
immunity,  and  similarly  exposure  to  blood-stage  parasites  can  afford  pre-erythrocytic  immunity.
The incorporation  of  a blood-stage  component  into  a multi-stage  malaria  vaccine  would  hence  not  only
combat  breakthrough  infections  in  the blood  should  the  pre-erythrocytic  component  fail  to induce  sterile
protection,  but  would  also  actively  enhance  the pre-erythrocytic  potency  of  this  vaccine.  We  therefore
advocate  that  future  studies  should  concentrate  on  the  identiﬁcation  of  cross-stage  protective  malaria
antigens,  which  can  empower  multi-stage  malaria  vaccine  development.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Malaria remains a major global health scourge and there is
a general consensus that elimination and eradication efforts will
not be successful without an effective malaria vaccine. In malaria
endemic areas, immunity against severe disease caused by blood-
stage parasites can be acquired after only one or two infections,
while infections with high parasite densities still occur [1]. Vac-
cines targeting blood-stage parasites should equally induce control
of (severe) disease but ultimately also clearance of blood-stage
parasites. This is essential as gametocytes form during blood-stage
infection and transmission to mosquitoes can otherwise continue.
Abbreviations: AMA-1, apical membrane antigen 1; CPS, chemoprophylaxis and
sporozoites; iv, intravenous; MSP-1, merozoite surface protein 1.
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There is only very limited evidence for protection against
pre-erythrocytic malaria parasites (sporozoites and liver-stage
parasites) in naturally exposed populations [2–4]. Pre-erythrocytic
vaccines aim to outperform naturally acquired immunity by tar-
geting the clinically silent stages of infection thus precluding any
parasites reaching the blood stream. This would abolish any symp-
toms of malaria and additionally block transmission. The risk
of such an approach is however that breakthrough blood-stage
infections can cause severe complications, if the pre-erythrocytic
vaccine is only partially effective. Therefore a blood-stage compo-
nent should be included to minimize this risk [5,6]. This is especially
important since it was suggested that declining transmission inten-
sity and thus reduced boosting of clinically protective blood-stage
immunity could in fact increase overall malaria morbidity [7].
The desired scenario would therefore be to develop a multi-stage
malaria vaccine that minimizes both transmission and disease [8].
2. Hypothesis: Shared antigenic targets between liver and
blood-stage parasites can induce cross-stage immunity
Given that there are shared antigens between the different
life cycle stages of the malaria parasite [9], it is possible that
functional immunity to pre-erythrocytic and blood-stage parasites
http://dx.doi.org/10.1016/j.vaccine.2015.09.098
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could enhance each other, offering an intriguing possibility for
development of a multi-stage malaria vaccine. Evidence for cross-
stage immunity comes from several studies [10–13]. For instance,
apical membrane antigen (AMA)-1 and the unprocessed form of
merozoite surface protein (MSP)-1 are highly abundant in blood-
stage parasites with roles in erythrocyte invasion [14,15]; however
these antigens are also expressed by sporozoites and liver-stage
parasites [16,17]. In human volunteers immunized with AMA-1
the number of blood-stage parasites during the ﬁrst blood-stage
cycle after mosquito bite challenge infection was about 7-times
lower compared to non-immunized controls, suggesting that pre-
erythrocytic immune responses may  have eliminated sporozoites
or infected hepatocytes [13]. Indeed an 80% reduction of liver-stage
parasite burden following sporozoite challenge was shown in mice
immunized with AMA-1 [10]. After vaccination of humans with
AMA-1 and MSP-1, time to diagnosis, which was  delayed in the
vaccinees, signiﬁcantly correlated with liver-to-blood parasite lev-
els but not blood-stage multiplication rates. This suggests again that
this vaccine may  induce pre-erythrocytic rather than the originally
intended blood-stage immunity [12]. These examples indicate that
only one or two malarial antigens, which are expressed in both
liver- and blood-stage parasites, can induce cross-stage protective
immunity. Whole parasite vaccines that allow exposure to many
parasite antigens should therefore provide greater potential for
cross-stage immunity, which would enhance protection induced by
pre-erythrocytic and blood-stage parasites. We  therefore discuss
evidence for cross-stage immunity from different whole parasite
vaccination approaches, which offers the opportunity to identify
as yet unknown cross-protective antigens for multi-stage malaria
vaccine development.
3. Evidence for cross-stage immunity from
pre-erythrocytic whole parasite vaccination approaches
The proteome of liver-stage parasites becomes increasingly
similar to blood-stage parasites as liver development proceeds
[9]. Late liver-stage schizonts contain up to 40,000 merozoites
each [18], which can upon release invade erythrocytes. Further-
more the amount of parasite antigen increases as the parasite
matures in hepatocytes. Killed sporozoites that fail to invade
hepatocytes are incapable of inducing protection [19,20], suggest-
ing that liver-stage development is indispensable for induction
of protective immunity. Irradiation of sporozoites, which arrests
their development early during the liver-stage [21,22], induces
immunity to pre-erythrocytic stages only [19,23]. A very limited
number of studies have, however, investigated whether there
are signiﬁcant immune responses, or any level of protection
against blood-stage parasites. One report from Krzych et al.
[24] suggests a more in-depth study of cross-stage immune
responses induced by irradiation attenuated sporozoites might
be valuable, as T cells from human volunteers immunized with
irradiated sporozoites responded to both pre-erythrocytic and
blood-stage antigens, including MSP-1. This response was greater
in immunized volunteers, who were protected from challenge
infection, than in unprotected volunteers and comparable to
malaria-experienced individuals [24]. Therefore, immunization of
humans with irradiated sporozoites leads to the induction of
immune responses recognizing blood-stage antigens. CD8T cells,
which were shown to be essential for pre-erythrocytic protection
following irradiated sporozoites immunization [25], proliferate
more strongly in mice if in addition to Plasmodium berghei
irradiated sporozoites they were exposed to blood-stage para-
sites [26]. This suggests that blood-stage infection can enhance
pre-erythrocytic vaccine efﬁcacy. Furthermore in a P. berghei infec-
tion model in mice, multiple booster immunizations with high
numbers of irradiated sporozoites resulted in delayed patency and
reduced peak blood-stage parasitemia after sporozoite challenge
(Nganou-Makamdop K, personal communication), suggesting that
cross-stage protective responses targeting blood-stage parasites
may have developed. It has however also been observed that a
fulminant blood-stage infection can suppress protective immune
responses elicited by irradiated sporozoites against liver-stage
antigens [27]. Possible negative interferences between immunity
directed against liver and blood-stage parasites can therefore not be
excluded.
Targeted deletion of parasite genes important for liver-stage
development is an alternative strategy to arrest parasite devel-
opment in hepatocytes. Similar to irradiated and chemically
attenuated [28] sporozoites, immunization with knock-out para-
sites that arrest during the early liver-stage (e.g. uis 3 [29], uis 4 [30],
p36p [31], sap-1 [32], p52/p36 [33,34]) results in pre-erythrocytic
immunity. Late arrest during liver-stage development [35], how-
ever, appears to increase the chance of cross-stage immunity:
Immunization with P. yoelii fabb/f knockout sporozoites can control
and clear blood-stage parasitemia following challenge with blood-
stage parasites, possibly by inducing an effective T cell response
[36]. This is the ﬁrst direct evidence that immunization with an
attenuated parasite, which does not develop beyond liver-stage,
can elicit blood-stage immunity.
Cross-stage immunity therefore appears to be more efﬁcient if
liver-stage parasites arrest late in development as their antigenic
proﬁle becomes similar to blood-stage parasites [9] and the amount
of antigen increases (Fig. 1). Hence antigens expressed in late liver-
stage parasites are, under certain conditions, capable of mediating
not only pre-erythrocytic protection, but also reduce the risk of
blood-stage breakthrough infection by inducing effective blood-
stage immunity.
4. Evidence for cross-stage immunity from whole
blood-stage parasite vaccination approaches
Plasmodium replicates massively in the liver such that one
infected hepatocyte can release up to up to 40,000 blood-stage
parasites [37]. Also due to their subsequent exponential multi-
plication, blood-stage parasites are hence much more numerous
than pre-erythrocytic parasites, which increases their potential
to present protective antigens successfully. The possibility that
immune responses against these antigens might not be only speciﬁc
for blood-stage parasites, but could also target pre-erythrocytic
stages has however hardly been investigated (Fig. 1).
Disruption of the purine nucleoside phoshphorylase gene (pnp)
[38] or nucleoside transporter 1 (nt1) gene [39] in P. yoelii gives
rise to severely attenuated blood-stage infections, and mice that
had undergone an infection with these knockout parasites did not
develop detectable patent blood-stage parasitemia after infectious
mosquito bite or sporozoite challenge [38,39]. This could repre-
sent effective blood-stage or pre-erythrocytic immunity, since a
reduction in liver parasite burden, which is the only direct evidence
for pre-erythrocytic protection, was not shown. Direct evidence for
pre-erythrocytic protection elicited by blood-stage parasites comes
from mice that received a prophylactic treatment with chloroquine
and were simultaneously infected with P. yoelii blood-stage para-
sites. Liver parasite burden is signiﬁcantly reduced in these mice
following sporozoite challenge [40].
It is presumed that the main purpose of blood-stage compo-
nents in a multi-stage vaccine is to protect against breakthrough
blood-stage infection [41], if the pre-erythrocytic components are
only partially effective. However, since whole parasite blood-stage
immunizations have the potential to also induce cross-stage pro-
tective responses enhancing immunity against pre-erythrocytic
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Fig. 1. Shared antigens between liver and blood-stage malaria parasites can induce cross-stage immunity.
Malaria infection is initiated by an infectious mosquito bite, which inoculates a few sporozoites into the skin. Sporozoites then migrate to the liver and invade hepatocytes.
During  pre-erythrocytic development (which last 7 days for Plasmodium falciparum) parasite load slowly increases as Plasmodium matures in the liver. In addition, the
antigenic repertoire becomes increasingly similar to blood-stage parasites [9] and cross-stage antigens are expressed. Late liver schizonts contain up to 40,000 merozoites
[18], which are released into the blood-stream as merosomes surrounded by a host cell membrane [53]. When each merozoite invades an individual red blood cell parasite
load  rises rapidly. Blood-stage parasites mature from rings to trophozoites and schizonts and parasite load increases exponentially with each new replication cycle (P.
falciparumtakes  48h to complete one blood-stage cycle). Apart from typical blood-stage antigens infected erythrocytes also express cross-stage antigens, which are shared
with  pre-erythrocytic parasites. There is evidence from subunit and whole parasite immunization approaches that shared antigens between pre-erythrocytic and blood-stage
parasites could induce cross-stage immunity. Characterization of these antigens would greatly facilitate multi-stage malaria vaccine development.
stages, blood-stage antigens might be even more valuable for multi-
stage malaria vaccine development.
5. Is cross-stage immunity responsible for the
unprecedented efﬁciency of chemoprophylaxis with
sporozoites immunization?
The induction of cross-stage immunity should be facilitated by
exposure to both pre-erythrocytic and blood-stage parasites during
immunization. Chemoprophylaxis with sporozoites (CPS) immu-
nization, which uses infectious wild-type sporozoites combined
with prophylactic antimalarial drug treatment (often chloroquine),
allows the immune system to experience all vertebrate Plasmo-
dium life cycle stages including sporozoites, infected hepatocytes
and blood-stage parasites. CPS immunization was ﬁrst described
in rodents [42,43] and was later shown to induce long lasting
sterile protection against homologous mosquito-bite challenge in
human volunteers [44–46]. In humans CPS immunization is about
20 times more efﬁcient than immunization with irradiated sporo-
zoites [23,47]. We  therefore hypothesize that the completion of
liver-stage development and the exposure to blood-stage parasites
[40] during CPS immunization may  enhance the protective efﬁcacy
by inducing protective cross-stage responses. CPS immunization
using primaquine – a drug that primarily targets liver-stage para-
sites – substantially reduces the number of sterilely protected
mice thereby strengthening this hypothesis [20]. In further sup-
port of this, mice that have experienced a self-cured infection
with P. chabaudi blood-stage parasites derived from a donor mouse
infected by mosquito bite have a substantially reduced liver-
parasite burden following mosquito bite challenge [48]. Cross-stage
immunity elicited by blood-stage parasites may  hence contribute to
the unprecedented efﬁciency of CPS immunization to induce sterile
pre-erythrocytic protection in human volunteers [44–46]. Impor-
tantly exposure to blood-stage parasites during CPS immunization
may  signiﬁcantly contribute to the observed pre-erythrocytic pro-
tection against mosquito bite challenge, but does not appear to
protect against direct blood-challenge within the ﬁrst four cycles
of blood-stage replication [45]. In human volunteers CPS immu-
nization induces both T cell and antibody responses, which may
be implicated in protection [46,49–51]. Protective target antigens
and the exact mechanism of protective immunity are however still
unclear.
6. Conclusion: Importance of studying cross-stage
immunity for malaria vaccine development
Cross-stage immunity would be a powerful means to improve
protective efﬁcacy of malaria vaccines, however data to support
this hypothesis are sparse. During liver-stage development both
the amount of antigen and the antigenic similarity to blood-stage
parasites increases (Fig. 1). Thus as Plasmodium matures in the liver,
it is potentially capable of inducing immunity not only against pre-
erythrocytic but also against blood-stage parasites [36]. Equally,
exposure to attenuated blood-stage parasites could protect against
sporozoite challenge [40].
Future studies should therefore investigate the potential of
cross-stage immunity directly. In our opinion whole parasite
immunization approaches are particularly useful to answer the
question whether cross-stage immunity contributes to protec-
tion and to identify protective cross-stage antigens for subunit
malaria vaccine development. If however a whole parasite immu-
nization strategy were proven to be safe, effective and practical
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ﬁrst, there would be no reason not to implement it. Pre-erythrocytic
vaccines should evaluate blood-stage protection after direct injec-
tion of blood-stage parasites, while blood-stage vaccines should
demonstrate whether liver-parasite burden is reduced follow-
ing sporozoite challenge. If cross-stage immune responses can
be elicited, target antigens and crucial immunological mecha-
nisms mediating it should be characterized using proteome-wide
screening approaches (immunomics) of antibody and T cell reac-
tivity comparing protected and unprotected individuals [51,52].
Selecting antigens capable of inducing cross-stage protection could
greatly facilitate the development of a multi-stage malaria vaccine
by increasing potency.
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